ARTICLE | Emerging Company Profile
Callidus: Chemical conjugation
Callidus uses IGF-2 chemical conjugation for Pompe's enzyme replacement therapy
September 30, 2013 7:00 AM UTC
Callidus Biopharma Inc. is developing a compound for Pompe's disease that links a therapeutic enzyme with a targeting peptide that could lead to more efficient delivery to diseased tissue and therefore require lower doses than marketed enzyme replacement therapies.
Callidus also believes its lead compound could be safer than a later-stage compound from BioMarin Pharmaceutical Inc. that uses a similar targeting peptide...